NCT05841095View on ClinicalTrials.gov

Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

November 1, 2025

Conditions
Chronic Hepatitis b
Interventions
DRUG

ISA104

SLP vaccine

DRUG

Placebo

Saline solution (0.9% NaCl)

Trial Locations (1)

Unknown

RECRUITING

Erasmus MC, Rotterdam

Sponsors

Collaborators (1)

ISA Pharmaceuticals B.V.
All Listed Sponsors
collaborator

ISA Pharmaceuticals B.V.

INDUSTRY

lead

Erasmus Medical Center

OTHER

NCT05841095 - Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 | Biotech Hunter | Biotech Hunter